Friday, July 10, 2026

pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib

Sun Yat-sen University

Sun Yat-sen University clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

广州市新港西路135号, CN HQ
3,680 Employees
NMPA registrant Type
Company details
Status
Public
HQ
广州市新港西路135号, CN
Employees
3,680
Programs
19
Drugs
25
Patents
0
Intelligence · Clinical Programs

Sun Yat-sen University projects

19 ClinicalTrials.gov programs sponsored by Sun Yat-sen University.

Sun Yat-sen University has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial
  2. Cytokine-Induced Killer Cells

    Sun Yat-sen University

    Carcinoma, Hepatocellular

    phase 3 mab completed

    1 trial
  3. Palliative Chemotherapy

    Sun Yat-sen University

    Colorectal Neoplasms Malignant

    phase 3 small molecule active

    1 trial
  4. gemcitabine and cisplatin (Induction chemotherapy)

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial
  5. postoperative antimicrobial prophylaxis

    Sun Yat-sen University

    Hepatocellular Carcinoma

    phase 3 small molecule on hold

    1 trial
  6. Almonertinib

    Sun Yat-sen University

    Safety of Almonertinib

    phase 2 small molecule active

    1 trial
  7. Bone marrow mesenchymal stem cells (low dose)

    Sun Yat-sen University

    Acute-On-Chronic Liver Failure

    phase 2 small molecule active

    1 trial
  8. Chidamide

    Sun Yat-sen University

    Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial
  9. Online adaptive SBRT

    Sun Yat-sen University

    Adaptive Radiotherapy

    phase 2 other active

    1 trial
  10. Probiotics Compound (Biolosion)

    Sun Yat-sen University

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial
  11. Pucotenlimab

    Sun Yat-sen University

    Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial
  12. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial
  13. TPC induction chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial
  14. furmonertinib

    Sun Yat-sen University

    Non-small Cell Lung Cancer Metastatic

    phase 2 small molecule completed

    1 trial
  15. Concurrent chemotherapy

    Sun Yat-sen University

    Locally Advanced Lung Carcinoma

    phase 1 small molecule completed

    1 trial
  16. Benazepril

    Sun Yat-sen University

    Renal Function Disorder

    small molecule completed

    1 trial
  17. Probiotics

    Sun Yat-sen University

    Cardiometabolic Risk Factors

    other completed

    1 trial
  18. Terlipressin

    Sun Yat-sen University

    Septic Shock

    small molecule active

    1 trial
  19. araboxylan

    Sun Yat-sen University

    Subjects With Hyperuricemia

    other active

    1 trial

Frequently asked questions

How many clinical projects does Sun Yat-sen University have?

19 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.